Jazz Reports Phase 3 Success for Ziihera in HER2+ GEA
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
IRVING, Texas, May 5, 2026 Caris Life Sciences has announced the launch of Caris MI Clarityâ„¢, an advanced AI-powered...
SAN DIEGO, May 6, 2026 Gallant, an emerging animal health biotechnology company focused on regenerative veterinary medicine, has announced...
